Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Yasutaka Shimotsuura"'
Autor:
Toshimitsu Tanaka, Sachiko Nagasu, Takuya Furuta, Mizuki Gobaru, Hiroyuki Suzuki, Yasutaka Shimotsuura, Jun Akiba, Masatoshi Nomura, Fumihiko Fujita, Takumi Kawaguchi, Keisuke Miwa
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
The occurrence of fulminant type 1 diabetes mellitus as an adverse event during cancer immunotherapy has been previously reported. However, little is known about the causal relationship between the coronavirus disease 2019 (COVID-19) vaccination and
Externí odkaz:
https://doaj.org/article/4d81a074547b45d0af6ac095616563e5
Autor:
Etsuko Moriyama, Sachiko Nagasu, Toshimitsu Tanaka, Yasutaka Shimotsuura, Takeharu Ono, Hirohito Umeno, Jun Akiba, Akihiko Kawahara, Fumihiko Fujita, Takumi Kawaguchi, Keisuke Miwa
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionExpression of the NTRK gene is rare in solid tumors but is highly prevalent in salivary gland secretory carcinomas. Here, we report a case of a complete response to entrectinib in a patient with NTRK fusion gene-positive parotid carcinoma
Externí odkaz:
https://doaj.org/article/45cb8b3a60314a6b90e4a2ad32d1cbf3
Autor:
Toshimitsu Tanaka, Sachiko Nagasu, Takuya Furuta, Mizuki Gobaru, Hiroyuki Suzuki, Yasutaka Shimotsuura, Jun Akiba, Masatoshi Nomura, Fumihiko Fujita, Takumi Kawaguchi, Keisuke Miwa
Publikováno v:
Frontiers in Oncology; 2024, p1-6, 6p
Autor:
Tetsuya Eto, Yasutaka Shimotsuura, Tatsuto Terada, Maika Natsume, Tomofumi Miura, Midori Yuki Yajima, Kazuhiro Kosugi, Yoshihisa Matsumoto
Publikováno v:
Traditional & Kampo Medicine. 9:57-60
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6a30db577b34fab4dbd4acaf7f8e27fd
https://doi.org/10.1002/tkm2.1302
https://doi.org/10.1002/tkm2.1302
Autor:
Hirona Shigyo, Hiroyuki Suzuki, Toshimitsu Tanaka, Etsuko Moriyama, Yasutaka Shimotsuura, Sachiko Nagasu, Hideki Iwamoto, Yoshito Akagi, Kenta Murotani, Takumi Kawaguchi, Keisuke Miwa
Publikováno v:
Cancers; Volume 15; Issue 8; Pages: 2264
Bevacizumab (BEV) requires an adequate withdrawal period to avoid BEV-related complications during major surgery. However, the safety of BEV administration immediately after surgical placement of the central venous (CV) port, a minor surgery, is stil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4abde0b2416e416453b3eb4803bab32a
https://doi.org/10.3390/cancers15082264
https://doi.org/10.3390/cancers15082264
Autor:
Osamu Takasu, Masakazu Nabeta, Tomonori Cho, Takanori Muta, Kei Fukami, Masafumi Fukuda, Yutaka Shimamatsu, Yasutaka Shimotsuura
Publikováno v:
Medicine. 99:e21743
Introduction FOLFOX therapy is the main chemotherapy regimen for colorectal cancer. Peripheral neuropathy, hematotoxicity, and digestive symptoms are known to be the most frequent adverse events. Hyperammonemia and lactic acidosis rarely occur simult
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::07529bf1fdd51c4ca9f63cfbb4796419
https://doi.org/10.1097/md.0000000000021743
https://doi.org/10.1097/md.0000000000021743